<DOC>
	<DOCNO>NCT01953874</DOCNO>
	<brief_summary>The aim study compare effect MV target ASV addition optimize medical therapy versus optimize medical therapy alone 6 month patient acute decompensated HF . The study also assess change functional parameter , biomarkers , quality life ( QOL ) , sleep .</brief_summary>
	<brief_title>Cardiovascular Improvements With MV ASV Therapy Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<criteria>Patients 21 year old Patients prior clinical diagnosis heart failure ( HFrEF HFpEF ) , de novo diagnosis HFpEF indicate local BNP≥300 pg/mL NT proBNP≥1200 pg/mL admission without systolic blood pressure &gt; 180 mmHg atrial fibrillation , diagnosis HFrEF indicate documented evidence prescribe betablockers ACEinhibitors ARBs least 4 week prior admission Hospital admission acute decompensated HF determine : Dyspnea rest minimal exertion AND At least two follow sign symptom : Orthopnea Pulmonary rales beyond basilar Chest congestion xray BNP≥300pg/mL NT proBNP≥1200pg/mL Pulmonary capillary wedge pressure ( PCWP ) ≥25mmHg current hospitalization Presented hospital clinic least 24 hour prior consent Patient stable enough stop oxygen use duration polygraphy test access dual lumen cannula polygraphy test Sleep disorder breathing ( SDB ) document polygraphy AHI≥15 events/hour Patient able fully understand study information sign consent form Rightsided heart failure without leftsided heart failure Sustained systolic blood pressure &lt; 80 mmHg baseline Acute coronary syndrome within 1 month randomization Active myocarditis Complex congenital heart disease Constrictive pericarditis Noncardiac pulmonary edema Clinical evidence digoxin toxicity Need mechanical hemodynamic support time randomization Oxygen saturation ≤85 % rest day start nocturnal oximetry record regular use oxygen therapy ( day night ) COPD exacerbation primary reason hospital admission Current use ( within 4 week study entry ) PAPtherapy ( eg , fix , bilevel , APAP ) Life expectancy &lt; 1 year disease unrelated HF Transient ischemic attack ( TIA ) Stroke within 3 month prior randomization CABG procedure within 3 month prior randomization , plan occur study period CRT implant within 3 month prior randomization , plan occur study period VAD implant plan occur study period Heart transplant list Status 1a 1b Status posttransplant LVAD Prescribed inotrope therapy anticipate discharge Chronic Dialysis Known amyloidosis , hypertrophic obstructive cardiomyopathy , arteriovenous fistula Primary hemodynamically significant uncorrected valvular heart disease ( obstructive regurgitant ) plan intervention within 6 month randomization Pregnant , plan become pregnant Can tolerate ASV treatment runin Can perform 6MWT baseline Occupation commercial driver pilot plan perform activity study period Inability comply plan study procedure Participation pharmaceutical treatmentrelated clinical study within 1 month study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>acute decompensated heart failure</keyword>
	<keyword>chronic heart failure</keyword>
	<keyword>left-sided heart failure</keyword>
	<keyword>heart failure decompensation</keyword>
	<keyword>sleep apnea</keyword>
	<keyword>sleep disorder breathing</keyword>
	<keyword>central sleep apnea</keyword>
	<keyword>obstructive sleep apnea</keyword>
	<keyword>cheyne-stokes respiration</keyword>
</DOC>